|
1）Gauld DR, Pain MC, Rubinfeld AR. Beta-blocking drugs and airways obstruction. Med J Aust. 1979; 2: 88
|
|
|
|
2）Raine JM, Palazzo MG, Kerr JH, et al. Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. Br Med J (Clin Res Ed). 1981; 282: 548-9
|
|
|
|
|
|
3）Williams IP, Millard FJ. Severe asthma after inadvertent ingestion of oxprenolol. Thorax. 1980; 35: 160
|
|
|
|
|
4）Chang CL, Mills GD, McLachlan JD, et al. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J. 2010; 40: 193-200
|
|
|
|
|
|
5）van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest. 2005; 127: 818-24
|
|
|
|
|
|
6）Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; (4): CD003566
|
|
|
|
|
|
7）Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective β-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002; 137: 715-25
|
|
|
|
|
|
8）Dorow P, Thalhofer S, Bethge H, et al. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J Cardiovasc Pharmacol. 1990; 16 Suppl 5: S36-44
|
|
|
|
|
|
9）Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010; 55: 1780-7
|
|
|
|
|
|
10）Gottlieb SS, McCarter RJ, Vogel RA. Effect of β-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998; 339: 489-97
|
|
|
|
|
|
11）van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective β-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008; 178: 695-700
|
|
|
|
|
|
12）Staszewsky L, Wong M, Masson S, et al. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail. 2007; 13: 797-804
|
|
|
|
|
|
13）Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010; 170: 880-7
|
|
|
|
|
|
14）Short PM, Lipworth SI, Elder DH, et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011; 342: d2549
|
|
|
|
|
|
15）Heindl S, Lehnert M, Criée CP, et al. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001; 164: 597-601
|
|
|
|
|
|
16）Sakamaki F, Oya H, Nagaya N, et al. Higher prevalence of obstructive airway disease in patients with thoracic or abdominal aortic aneurysm. J Vasc Surg. 2002; 36: 35-40
|
|
|
|
|
|
17）Volterrani M, Scalvini S, Mazzuero G, et al. Decreased heart rate variability in patients with chronic obstructive pulmonary disease. Chest. 1994; 106: 1432-7
|
|
|
|
|
|
18）Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 187: 715-20
|
|
|
|
|
|
19）Chen J, Radford MJ, Wang Y, et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001; 37: 1950-6
|
|
|
|
|
|
20）Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2013. Available from http://www.goldcopd.org/
|
|
|
|
|
|
21）Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008; 29: 2388-442
|
|
|
|
|
|
22）Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119: e391-479
|
|
|
|
|
|
23）Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007; 116: e148-304
|
|
|
|
|
|
24）日本高血圧学会．日本高血圧学会高血圧治療ガイドライン作成委員会，編．高血圧治療ガイドライン2009．東京：ライフサイエンス出版；2009
|
|
|
|
|
|
25）Clini EM, Beghé B, Fabbri LM. Chronic obstructive pulmonary disease is just one component of the complex multimorbidities in patients with COPD. Am J Respir Crit Care Med. 2013; 187: 668-71
|
|
|
|
|